TrovaGene, Inc. (TROV) Shares Up 7.6%
TrovaGene, Inc. (NASDAQ:TROV) shares shot up 7.6% during mid-day trading on Friday . The company traded as high as $0.75 and last traded at $0.71, with a volume of 502,213 shares trading hands. The stock had previously closed at $0.66.
A number of brokerages have issued reports on TROV. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a research note on Wednesday, August 16th. Cantor Fitzgerald restated an “overweight” rating on shares of TrovaGene in a research note on Tuesday, August 8th.
The firm has a 50-day moving average of $0.86 and a 200-day moving average of $1.08. The stock’s market capitalization is $26.46 million.
Hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC boosted its stake in TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock worth $139,000 after buying an additional 87,264 shares during the period. LMR Partners LLP purchased a new stake in TrovaGene during the second quarter worth approximately $151,000. Susquehanna International Group LLP boosted its stake in TrovaGene by 2,781.0% in the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after buying an additional 133,240 shares during the period. KCG Holdings Inc. boosted its stake in TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after buying an additional 178,440 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in TrovaGene by 1,079.5% in the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after buying an additional 254,601 shares during the period. Institutional investors own 9.09% of the company’s stock.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.